Fusion Genomics Receives $1 Million Award to Evaluate Novel Genomic Diagnostics Platform in Collaboration with Sunnybrook Research Institute

  10 January 2020

Fusion Genomics announced that the company has been awarded $1 million to conduct a prospective clinical study evaluating its ONETest™ comprehensive, novel genomic diagnostics platform. The study is funded through the CQDM Quantum Leap program, which supports exploration of innovative technologies, tools, and platforms that accelerate or facilitate drug discovery and development. Merck is supporting the study as a member of CQDM, and Fusion Genomics will collaborate with Sunnybrook Research Institute to conduct the study.

Author(s): Business Wire
Smart Innovations  

Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market (max 5)
  • Global reach for funding / co-development / licensing
Display your technology >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!